
COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.
What To Know: The study evaluated COMP360, a single-dose treatment consisting of a synthetic, proprietary formulation of psilocybin, for people with treatment-resistant depression.